Scanbase vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
Computer vision API reading at-home lateral flow test photos for 40+ test types; $3M revenue with 5-person team enabling telehealth result verification for COVID, flu, and STD tests.
About
Scanbase is a healthcare technology company providing a computer vision API that enables medical and consumer health companies to analyze at-home diagnostic test results through smartphone photos — reading lateral flow tests (the strip-based rapid tests used for COVID-19, flu, RSV, strep, pregnancy, and STDs) and returning structured results that can be recorded in health apps, telehealth platforms, and clinical systems. Founded in 2022 in San Francisco and a Y Combinator W23 graduate, Scanbase raised $2.5 million from Dupe Ventures and Liquid 2 Ventures, achieving $3 million in revenue in 2024 with a 5-person team.\n\nScanbase's API integrates into health apps, telehealth platforms, and employee health programs — when a user takes a photo of their at-home test strip, the API analyzes the image to detect control line and test line presence/intensity, returning a validated result (positive, negative, invalid) with confidence scores. This replaces manual result entry (prone to misinterpretation) and photo review by human staff with automated, consistent computer vision interpretation. The API covers 40+ test types including COVID-19, flu A/B, RSV, pregnancy, and various STD tests.\n\nIn 2025, Scanbase competes in the digital diagnostics and at-home testing technology market with Sight Diagnostics, LumiraDx, and platform-specific solutions built by major diagnostics companies for at-home test result interpretation. The COVID-19 pandemic permanently expanded at-home testing adoption, creating a large installed base of consumers comfortable with lateral flow tests and a growing need for digital result capture and verification in telehealth workflows. The $3M ARR with a 5-person team demonstrates exceptional capital efficiency. The 2025 strategy focuses on expanding the test coverage library, growing integrations with telehealth and employee health platforms, and adding verification workflows for use cases where authenticated test results are needed (insurance claims, return-to-work programs).
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.